Table 2.
Neostigmine dose by last documented Train of Four (TOF) prior to reversal and Body Mass Index (BMI) category for cases receiving Neostigmine
| Cases receiving first dose | Initial dose (mcg/kg) | Cases receiving second dose | Time between first and second doses (minutes) | Second dose (mcg/kg) | Cases receiving third dose | Time between second and third doses (minutes) | Third dose (mcg/kg) | Total dose (mcg/kg) | |
|---|---|---|---|---|---|---|---|---|---|
| N a | Median [IQR] | N (%)a | Median [IQR] | Median [IQR] | N (%)a | Median [IQR] | Median [IQR] | Median [IQR] | |
| Last TOF prior to reversal | |||||||||
| 0/4 | 3520 | 37.0 [30.6, 42.4] | 192 (5.5) | 6 [2, 12] | 20.0 [14.2, 28.1] | 7 (0.2) | 5 [3, 8] | 22.4 [13.0, 23.9] | 37.9 [30.9, 43.7] |
| 1/4 | 6956 | 37.1 [30.8, 42.8] | 338 (4.9) | 6 [2, 11] | 17.3 [11.6, 24.8] | 18 (0.3) | 6 [3, 14] | 16.8 [13.8, 27.8] | 37.8 [31.3, 43.9] |
| 2/4 | 7713 | 37.2 [30.9, 42.2] | 267 (3.5) | 7 [2, 13] | 15.8 [10.8, 25.0] | 11 (0.1) | 7 [2, 9] | 11.1 [8.1, 18.1] | 37.6 [31.1, 42.7] |
| 3/4 | 7133 | 36.8 [30.7, 41.9] | 166 (2.3) | 5 [1, 12] | 14.5 [10.1, 22.3] | 11 (0.2) | 7 [3, 10] | 14.7 [10.6, 17.9] | 37.0 [30.8, 42.3] |
| 4/4 | 81,958 | 37.5 [30.6, 41.7] | 1136 (1.4) | 5 [1, 12] | 14.7 [9.9,22.1] | 73 (0.1) | 3 [1, 6] | 11.3 [9.3, 15.2] | 37.5 [30.6, 41.7] |
| Undocumented | 9105 | 34.5 [29.4, 41.1] | 217 (2.4) | 6 [2, 11] | 17.9 [11.1, 26.7] | 10 (0.1) | 9 [4, 16] | 14.1 [11.6, 17.5] | 35.0 [29.4, 41.5] |
| WHO BMI categoryb | |||||||||
| Underweight | 2456 | 42.6 [36.6, 49.2] | 50 (2.0) | 10 [4, 15] | 22.7 [19.3, 31.3] | 1 (0.0) | 15 [15, 15] | 24.1 [24.1, 24.1] | 42.8 [36.8, 50.0] |
| Normal weight | 32,491 | 39.4 [33.3, 44.4] | 574 (1.8) | 6 [2, 12] | 19.2 [14.4, 29.9] | 31 (0.1) | 6 [2, 9] | 17.2 [14.3, 23.9] | 39.7 [33.4, 44.8] |
| Overweight | 35,302 | 37.5 [31.1, 41.7] | 609 (1.7) | 6 [1, 11] | 15.6 [11.9, 25.5] | 42 (0.1) | 5 [2, 10] | 13.2 [10.8, 20.0] | 37.6 [31.3, 41.7] |
| Class I obese | 22,634 | 35.3 [29.7, 40.4] | 488 (2.2) | 5 [1, 13] | 14.4 [10.1, 22.2] | 26 (0.1) | 3 [1, 7] | 10.5 [9.4, 12.8] | 35.7 [29.8, 40.7] |
| Class II obese | 11,321 | 32.7 [28.1, 39.7] | 258 (2.3) | 4 [1, 11] | 11.9 [9.2, 19.6] | 14 (0.1) | 2 [1, 5] | 10.3 [9.0, 13.6] | 33.1 [28.4, 40.0] |
| Class III obese | 8973 | 30.5 [25.0, 37.0] | 284 (3.2) | 3 [0, 9] | 10.4 [7.5, 16.7] | 12 (0.1) | 4 [1,11] | 8.1 [7.0, 14.3] | 30.8 [25.3, 37.5] |
TOF train-of-four, WHO World Health Organization, BMI body mass index
aOnly among patients with TBW between 40 and 250 kg and receiving neostigmine
bOnly among patients with BMI between 10 and 80